Karen Chu

PAREXEL International Corp. provides biopharmaceutical services. It offers clinical research and logistics, medical communications, consulting, commercialization and advanced technology products and services for pharmaceutical, biotechnology and medical device industries. The company was founded in 1983 and is headquartered in Newton, MA.

Acesion Pharma ApS develops drugs for the treatment of atrial fibrillation (AF), the most common type of cardiac arrhythmia. The firm's technology blocks ion channel with a selective drug molecule constitutes a target for developing treatment of AF. The company was founded by Ulrik Svane S?rensen and Morten Grunnet in 2011 and is headquartered in Copenhagen, Denmark.

Cellestia Biotech AG manufactures anti-cancer drugs. Its pipeline product includes CB-103, a novel oral pan-NOTCH inhibitor for the treatment of NOTCH dependent leukemia, lymphoma, and solid tumors. The firm holds a worldwide exclusive license on the intellectual property rights for the development and commercialization of CB-103 and related series of close analogues. The company was founded by Freddy Radtke, Michael Bauer, Richard Peck, Dirk Weber and Rajwinder Lehal in 2014 and is headquartered in Basel, Switzerland.

Harvest Integrated Research Organization (HIRO) is a clinical research organization that provides cross-border solutions and services to its clients, including pre-clinical strategic planning, clinical trial design, regulatory, pharmacovigilance, statistics, data management, project management, and clinical and medical monitoring services. The private company is based in Shanghai, CN, and has subsidiaries in the United States. HIRO aims to become a market-leading, integrated clinical research organization that collaborates with biotech and pharmaceutical companies to bring new products to the market, providing more effective solutions for patients worldwide. The Chinese company was founded in 2020 by Karen Chu, who has been the CEO since then.